HAVCR2 and non-small cell lung carcinoma: Moreover, immune checkpoints such as PD-1/PD-L1, TIM-3, and TIGIT are known to play important roles in the treatment of NSCLC, OV, SKCM, BRCA, and have been recognized as biomarkers for immunotherapy response96,97.